Debiopharm News and Resources

Debiopharm, a Swiss biopharmaceutical company, has signed a co-research agreement with US-based Alkyon Therapeutics to evaluate the development of precision-targeted radioligand therapies (RLTs). The collaboration will combine Debiopharm’s proprietary AbYlink™ conjugation technology with Alkyon’s modular antibody platform targeting undisclosed tumour-associated antigens. The